Drug sponsors spend more on contract research organizations (CROs) to help develop new medicines than they do on internal staff and infrastructure, but outsourcing practices remain inconsistent and highly customized, inviting inefficiency and unsystematic management practice, according to an analysis recently completed by the Tufts Center for the Study of Drug Development
MaxCyte, the global cell-based medicines and life sciences company, announced today that it has expanded its relationship with Kite, a Gilead Company, by entering into a multi-drug clinical and commercial agreement
AbCellera recently announced an expanded collaboration with Denali Therapeutics Inc. to discover antibodies as therapies for neurological indications
Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to TransCon CNP, a long-acting prodrug of C-type natriuretic peptide (CNP) in development for children with achondroplasia
A unique non-profit and private partnership using a datathon and an AI-powered technology platform has identified new repurposable drug candidates to treat a painful chronic disease affecting about a million people globally and for which there is no current treatment
Healx, a Cambridge (UK) technology company, today announced a collaboration with Boston Children’s Hospital and Barth Syndrome Foundation (BSF) to advance promising therapeutic compounds using a novel approach that will accelerate drug discovery for applications in Barth syndrome, a life-threatening, genetic mitochondrial disease
NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), reported today that it has reached an agreement on the terms of the license for the drug development against VZV, the virus that causes chickenpox in children and shingles in adults
Most current medicines are derived from naturally occurring small molecules. Yet the lack of a systematic method for producing diverse nature-inspired small molecules has prevented the development of a wider range of new medications
A 3D hydrogel created by researchers in University Professor Molly Shoichet’s (ChemE, IBBME) lab is helping University of Ottawa researchers to quickly screen hundreds of potential drugs for their ability to fight highly invasive cancers
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced that it has submitted an Investigational New Drug (IND) application for CG-806 to the U.S. Food and Drug Administration (FDA) requesting approval to initiate its Phase 1 clinical trial program
|
|
|
|
|
|
|
|
|